BeiGene Ltd.
π¨π³China
- Country
- π¨π³China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
Phase 1
Completed
- Conditions
- Advanced Cancer
- Interventions
- Biological: BGB-A317
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 451
- Registration Number
- NCT02407990
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈOncology Consultants, P.A., Houston, Texas, United States
π¦πΊChris O'Brien Lifehouse, Camperdown, New South Wales, Australia
Phase 1a/1b BGB-290 for Advanced Solid Tumors.
Phase 1
Completed
- Conditions
- For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment
- Interventions
- First Posted Date
- 2015-02-12
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 101
- Registration Number
- NCT02361723
- Locations
- π¦πΊ
Cancer Care Wollongong, Wollongong, New South Wales, Australia
π¦πΊGosford Hospital, Gosford, New South Wales, Australia
π¦πΊFlinders Medical Centre, Bedford PK, South Australia, Australia
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 385
- Registration Number
- NCT02343120
- Locations
- πΊπΈ
Banner MD Anderson Cancer Centre, Gilbert, Arizona, United States
πΊπΈUniversity of Michigan, Ann Arbor, Michigan, United States
πΊπΈMayo Clinic, Rochester, Minnesota, United States